This article explores GLP-1s physiology, the difference between natural and drug-induced GLP-1 action, and how a healthy microbiome could offer a powerful, natural strategy to enhance GLP-1 function while avoiding some of the side effects commonly associated with pharmaceutical GLP-1 agonists
Weight loss of 710% of body weight has been shown to improve liver histology in NAFLD (as per NICE NG49 guidance), whilst glutathione's benefits remain unproven
issued a recall of its 7.4 ounce container of Boost Tea because it may be contaminated with Salmonella
IR refers to the inability of insulin to effectively promote glucose uptake in peripheral tissues or to inhibit hepatic glucose output, which leads to increased blood glucose
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
The dialyzed polymer was subsequently lyophilized and reconstituted in sterile phosphate-buffered saline (PBS) to a final concentration of 60 mg mL for use in hydrogel formulations